Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

 Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

Shots:

  • In the HIBISCUS I induction study, in patients without prior anti-TNF treatment, etrolizumab met its 1EPs while in HIBISCUS II study in the same kind of people, it did not meet its 1EPs. In the HICKORY study, in patients with prior anti-TNF treatment, therapy met its 1EPs at induction but not at maintenance
  • In the LAUREL maintenance study in people without prior anti-TNF treatment, etrolizumab failed to meet its 1EPs while the safety profile of therapy was consistent with previous studies and no major safety issues were reported till date in the four P-III studies
  • The therapy is currently being evaluated as an induction/maintenance treatment in people with mod. to sev. active CD with/out prior anti-TNF treatment in a global P-III study (BERGAMOT) and OLE and safety monitoring study (JUNIPER), involving 1,100+ people with CD. In addition, Roche is studying other therapies in IBD and is committed to further understanding this disease

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pantone Canvas Gallery

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post